in this issue
Regions :: Western Europe :: France
Sanofi-Aventis to Acquire U.S. Biopharma Firm
June 30, 2010 | Deepti Ramesh
Sanofi-Aventis (Paris) says it has signed an agreement to acquire TargeGen (San Diego, CA), a privately held biopharmaceutical company developing small molecule kinase inhibitors for the treatment of certain forms of leukemia, lymphoma and other hematological malignancies and blood disorders. Sanofi-Aventis will make an upfront payment of $75 million upon closing of the transaction, and further milestones payments at different stages of development of TargeGen lead product TG 101348. The total payments, including the upfront payment, could reach $560 million. The...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be: